Literature DB >> 16875736

Complement-related molecular events in sepsis leading to heart failure.

Laszlo M Hoesel1, Andreas D Niederbichler, Peter A Ward.   

Abstract

Despite intensive ongoing research efforts, the mortality of patients with sepsis remains unacceptably high. A significant number of clinical trials have failed to produce sufficient therapeutic strategies despite showing promising results in animal models. So far, many studies have focused on deterioration of the humoral and cellular components of the immune system, the main cause of death in septic patients being multi-organ failure. However, not much is known about the effects of the complement system on parenchymal cells of organs such as the heart. Recently, septic cardiomyopathy has been recognized as one of the major complications during sepsis, often determining the clinical outcome. In this review, we describe molecular events which are thought to be related to cardiac dysfunction during sepsis. A special emphasis will be placed on the complement system, which generates powerful anaphylatoxins (such as C5a) and which has recently been associated with septic cardiomyopathy. Together with the impact on cardiac function of various cytokines we will provide a synopsis of the current knowledge regarding the pathophysiology underlying cardiac failure during sepsis with a special emphasis on C5a and C5aR.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16875736     DOI: 10.1016/j.molimm.2006.06.009

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  22 in total

Review 1.  [Pathophysiological basis of surgery-linked sepsis].

Authors:  B Vollmar
Journal:  Chirurg       Date:  2011-03       Impact factor: 0.955

Review 2.  Sepsis-induced cardiomyopathy: a review of pathophysiologic mechanisms.

Authors:  Anthony Flynn; Bhalaghuru Chokkalingam Mani; Paul J Mather
Journal:  Heart Fail Rev       Date:  2010-11       Impact factor: 4.214

Review 3.  Role of complement C5a and histones in septic cardiomyopathy.

Authors:  Fatemeh Fattahi; Lynn M Frydrych; Guowu Bian; Miriam Kalbitz; Todd J Herron; Elizabeth A Malan; Matthew J Delano; Peter A Ward
Journal:  Mol Immunol       Date:  2018-06-18       Impact factor: 4.407

4.  Identification and Validation of Immune-Related Biomarker Gene and Construction of ceRNA Networks in Septic Cardiomyopathy.

Authors:  Jingru Li; Xinyu Wu; Chaozhong Li; Guihu Sun; Peng Ding; Yanyan Li; Ping Yang; Min Zhang; Luqiao Wang
Journal:  Front Cell Infect Microbiol       Date:  2022-06-16       Impact factor: 6.073

Review 5.  Complement and sepsis-induced heart dysfunction.

Authors:  Fatemeh Fattahi; Peter A Ward
Journal:  Mol Immunol       Date:  2016-12-05       Impact factor: 4.407

6.  Reversing established sepsis in rats with human vasoactive hormone adrenomedullin and its binding protein.

Authors:  Rongqian Wu; Shinya Higuchi; Weifeng Dong; Youxin Ji; Mian Zhou; Corrado P Marini; Thanjavur S Ravikumar; Ping Wang
Journal:  Mol Med       Date:  2008-10-10       Impact factor: 6.354

7.  High-mobility group box 1 induces calcineurin-mediated cell hypertrophy in neonatal rat ventricular myocytes.

Authors:  Fei-fei Su; Miao-qian Shi; Wan-gang Guo; Xiong-tao Liu; Hong-tao Wang; Zi-fan Lu; Qiang-sun Zheng
Journal:  Mediators Inflamm       Date:  2012-06-20       Impact factor: 4.711

Review 8.  Reversible Cardiomyopathies.

Authors:  Harsh Patel; Raef Madanieh; Constantine E Kosmas; Satya K Vatti; Timothy J Vittorio
Journal:  Clin Med Insights Cardiol       Date:  2015-05-21

9.  Erythropoietin attenuates cardiac dysfunction in experimental sepsis in mice via activation of the β-common receptor.

Authors:  Areeg I Khan; Sina M Coldewey; Nimesh S A Patel; Mara Rogazzo; Massimo Collino; Muhammed M Yaqoob; Peter Radermacher; Amar Kapoor; Christoph Thiemermann
Journal:  Dis Model Mech       Date:  2013-03-15       Impact factor: 5.758

Review 10.  Multiple organ dysfunction syndrome in humans and animals.

Authors:  K Osterbur; F A Mann; K Kuroki; A DeClue
Journal:  J Vet Intern Med       Date:  2014-04-28       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.